| Literature DB >> 35804413 |
Anju Sahay1, Brian S Mittman2, Parisa Gholami3, Shoutzu Lin3, Paul A Heidenreich3,4.
Abstract
BACKGROUND: Communities of Practice (CoPs) are a promising approach to facilitate the implementation of evidence-based practices (EBPs) to improve care for chronic conditions like heart failure (HF). CoPs involve a complex process of acquiring and converting both explicit and tacit knowledge into clinical activities. This study describes the conceptualization, creation, capacity-building and dissemination of a CoP sustained over 9 years, and evaluates its value and impact on EBP.Entities:
Keywords: Community of Practice; Evaluation; Formative evaluation; Health policy; Health systems; Quality improvement; Social network
Mesh:
Year: 2022 PMID: 35804413 PMCID: PMC9264639 DOI: 10.1186/s12961-022-00880-9
Source DB: PubMed Journal: Health Res Policy Syst ISSN: 1478-4505
Fig. 1Conceptual framework for the evaluation of the HF Network as a CoP
Mapping of Li’s characteristics of CoP groups to HF Network activities
| HF Network activities | Li’s characteristics of CoP groups | |||
|---|---|---|---|---|
| Social interaction | Knowledge-sharing | Knowledge creation | Identity-building | |
| Bimonthly web-based meetings with conference calls | ||||
| Annual in-person meeting | ||||
| Surveys—email text and web-based links | ||||
| Email exchange | ||||
| Non-mandated forum of VA SharePoint site to exchange ideas | ||||
| Revise CHF QUERI Strategic Plan | ||||
| Networking | ||||
| HF Programmes | ||||
| HF Provider Toolkit | ||||
| HF tools | ||||
| Patient and caregiver education materials | ||||
| Funds for projects | ||||
| Expand research activities | ||||
| Expand QI initiatives | ||||
| Recruit sites to conduct research and/or QI initiatives | ||||
| Formative evaluation of HF Network | ||||
| Collaborations | ||||
| HF experts | ||||
| New local opinion leaders and champions | ||||
| Development of subspecialty networks | ||||
Characteristics of all HF Network members
| Member role | Membership status (July 2006–June 2015) | |||
|---|---|---|---|---|
| Current member | Past member: | Past member: | Total | |
| Site/departmental leaders | 159 (11.9) | 27 (2.0) | 24 (1.8) | 210 (15.7) |
| VACO/VISN leaders | 43 (3.2) | 11 (0.8) | 12 (0.9) | 66 (4.9) |
| Other administrators | 28 (2.1) | 3 (0.2) | 5 (0.4) | 36 (2.7) |
| Quality management staff | 23 (1.7) | 3 (0.2) | 4 (0.3) | 30 (2.2) |
| Physicians | 255 (19.0) | 43 (3.2) | 110 (8.2) | 408 (30.4) |
| Nurses | 178 (13.3) | 33 (2.5) | 56 (4.2) | 267 (19.9) |
| Nurse practitioners | 95 (7.1) | 6 (0.4) | 20 (1.5) | 121 (9.0) |
| Pharmacists | 52 (3.9) | 5 (0.4) | 13 (1.0) | 70 (5.2) |
| Physician assistants | 11 (0.8) | 3 (0.2) | 3 (0.2) | 17 (1.3) |
| Psychologists | 6 (0.4) | 1 (0.1) | 1 (0.1) | 8 (0.6) |
| 57 (4.3) | 3 (0.2) | 10 (0.7) | 70 (5.2) | |
| 23 (1.7) | 7 (0.5) | 8 (0.6) | 38 (2.8) | |
| TOTAL | 930 (69.4) | 145 (10.8) | 266 (19.8) | 1341 (100.0) |
Fig. 2Sustainability of HF Network membership per year shown for all, new, past (opted out) and past (left VA) members
Fig. 3Member role and years of membership in HF Network
Fig. 4Member role and active versus passive members of the HF Network
Fig. 5Member role and level of active participation in the HF Network
Characteristics of members: responded to survey and all members
| Member role | Survey respondents | All HF Network |
|---|---|---|
| VACO/VISN leaders | 12 (5.5) | 66 (4.9) |
| Site/departmental leaders | 35 (16.0) | 210 (15.7) |
| Quality management staff | 6 (2.7) | 30 (2.2) |
| Administrators | 1 (0.5) | 36 (2.7) |
| Physicians | 50 (22.8) | 408 (30.4) |
| Nurse practitioners | 43 (19.6) | 121 (9.0) |
| Physician assistants | 4 (1.8) | 17 (1.3) |
| Nurses | 32 (14.6) | 267 (19.9) |
| Pharmacists | 15 (6.8) | 70 (5.2) |
| Psychologists | 0 (0.0) | 8 (0.6) |
| 17 (7.8) | 70 (5.2) | |
| 4 (1.8) | 8 (0.6) | |
| Total (%) | 219 (100) | 1341 (100) |
HF Network goals as perceived by members
| Goals | Goals of particular interest to members | Goals achieved by HF Network at least to a moderate extent |
|---|---|---|
| Share evidence-based HF programmes and updates in HF care | 219 (95.4) | 219 (97.3) |
| Understand the context in providing HF care (e.g. site, culture, leadership style, HF programme) | 219 (85.8) | 219 (90.6) |
| Learn about barriers and facilitators to improving HF care | 219 (92.2) | 219 (91.2) |
| Establish collaboration and/or network among members of the HF Network | 219 (88.6) | 219 (90.0) |
| Provide opportunities to identify/involve local champions at sites | 219 (73.5) | 219 (82.4) |
Fig. 6Benefit of participation for self-reported influential members
Characteristics of Sites Based on Site Participation Level
| Site characteristics | Site-level participation by members | |||
|---|---|---|---|---|
| None/low ( | Moderate ( | High | ||
| Tertiary care site | 13 (5.9) | 38 (17.4) | 78 (35.6) | 0.002** |
| Bed size | ||||
| 1–99 beds | 10 (4.8) | 5 (2.4) | 13 (6.3) | 0.01** |
| 100–199 beds | 7 (3.4) | 18 (8.7) | 17 (8.2) | |
| 200 or more beds | 19 (9.2) | 36 (17.4) | 82 (39.6) | |
| Member COTH (Council of Teaching Hospitals) | 14 (6.7) | 32 (15.2) | 62 (29.5) | 0.250 |
| Has ACGME (Accredited Graduate Medical Education) programme | 28 (13.3) | 53 (25.2) | 110 (52.4) | 0.005** |
| Has a cardiac cath lab | 36 (16.4) | 58 (26.5) | 119 (54.3) | 0.01** |
| Has on-site cardiologist services | 35 (16.0) | 61 (27.9) | 117 (53.4) | 0.005** |
| Has a HF clinic | 20 (9.1) | 50 (22.8) | 87 (39.7) | 0.004** |
| Use of pharmacist | 27 (12.3) | 45 (20.5) | 84 (38.4) | 0.860 |
| Standardized home monitoring | 29 (13.2) | 55 (25.1) | 98 (44.7) | 0.110 |
*P value significant at 0.05 level; **P value significant at 0.01 level
Average site quality indicators based on site-level participation by members
| Site characteristics during years 2–7 | Site-level participation by members | |||
|---|---|---|---|---|
| None/low | Moderate | High | ||
| ACE inhibitor | 0.963 (0.057) | 0.963 (0.047) | 0.979 (0.021) | 0.198 |
| Beta-blocker use* | 0.940 (0.067) | 0.946 (0.047) | 0.952 (0.044) | 0.565 |
| Use of aldosterone antagonist* | 0.230 (0.146) | 0.254 (0.122) | 0.275 (0.124) | 0.301 |
| Death 30 days after admission* | 0.068 (0.028) | 0.073 (0.031) | 0.062 (0.023) | 0.225 |
| Death at 1 year after admission* | 0.297 (0.068) | 0.285 (0.051) | 0.278 (0.040) | 0.245 |
| 30-Day all-cause readmission following discharge with principal diagnosis of HF | 0.165 (0.041) | 0.177 (0.038) | 0.191 (0.024) | 0.005 |
*Trends analysis